FDA approves weight-loss drug Zepbound to treat sleep apnea
Dec. 21 (UPI) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.
21 Dec 19:22 · UPI
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
20 Dec 21:39 · CNBC
last updated on 22 Dec 03:53